Lilly's (LLY) Alimta ANDA Receives FDA Paragraph IV Certification
Tweet Send to a FriendGet Alerts LLY Hot Sheet
Price: $54.14 -1.1%
Overall Analyst Rating:
NEUTRAL (
Down)
Dividend Yield: 3.5%
Revenue Growth %: 0.0%
Overall Analyst Rating:
NEUTRAL (
Down)Dividend Yield: 3.5%
Revenue Growth %: 0.0%
Trade LLY Now!
The FDA has given Eli Lilly's (NYSE: LLY) Alimta its Paragraph IV certification, according to the agency.
Lilly submitted its ANDA for Alimta on June 27, 2012. The submission was made for the 1000-mg vial.
Shares of Lilly are up 3 percent Monday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Lilly submitted its ANDA for Alimta on June 27, 2012. The submission was made for the 1000-mg vial.
Shares of Lilly are up 3 percent Monday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Corgenix Announces Diagnostic Development Agreement with Lilly
- Google (GOOG) Plans to Build Wireless Network in Africa and Southeast Asia - WSJ
- USEC Inc. (USU) to Halt Enrichment at Paducah Plant, Cut Workforce
Create E-mail Alert Related Categories
Corporate News, Fed
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
